| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7601746 | VANCOCIN ITALIA | Compounds exhibiting thrombopoietin receptor agonism |
Sep, 2024
(4 months from now) | |
| US8889722 | VANCOCIN ITALIA | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
Jul, 2028
(4 years from now) | |
| US8530668 | VANCOCIN ITALIA | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
Jan, 2030
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9427402 | VANCOCIN ITALIA | Preparation for improving solubility of poorly soluble drug |
Sep, 2031
(7 years from now) | |
Mulpleta is owned by Vancocin Italia.
Mulpleta contains Lusutrombopag.
Mulpleta has a total of 4 drug patents out of which 0 drug patents have expired.
Mulpleta was authorised for market use on 31 July, 2018.
Mulpleta is available in tablet;oral dosage forms.
Mulpleta can be used as treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
Drug patent challenges can be filed against Mulpleta from 31 July, 2022.
The generics of Mulpleta are possible to be released after 29 September, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 31, 2023 |
Drugs and Companies using LUSUTROMBOPAG ingredient
NCE-1 date: 31 July, 2022
Market Authorisation Date: 31 July, 2018
Treatment: Treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
Dosage: TABLET;ORAL
MULPLETA family patents
